Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma. - Arance A; Berciano-Guerrero MA; Guo J; Carlino MS; Ascierto PA; Burotto M; Mortier L; Queirolo P; Chiarion-Sileni V; Schachter J; Zhang X; Martin-Liberal J; et al. (Annals of oncology : official journal of the European Society for Medical Oncology, 2025)